AI Tackles Neglected Diseases
Curated by the Inblix editorial team
Anthropic is launching its own drug discovery programs to tackle diseases that Big Pharma considers unprofitable, aiming to research treatments for neglected diseases and build better AI models. The company’s move aligns with its nonprofit mission and could help speed up medical research. Novartis CEO Vas Narasimhan notes that new AI models could cut drug development time and double success rates, which would have a huge impact when scaled across major pharma. Why it matters: this development could significantly accelerate the discovery of new treatments and make previously unprofitable diseases viable for research and treatment.
💡 Key Takeaways
- Anthropic is launching its own drug discovery programs for neglected diseases considered unprofitable by traditional pharmaceutical companies.
- New AI models could cut drug development time from twelve years to seven or eight years and double success rates from 8 to 16 percent.
- Other AI companies, such as Google Deepmind and OpenAI, are also pushing into medicine with initiatives like Isomorphic Labs and ChatGPT Health.
Keep reading: See related articles below for more coverage on this topic.
Get smarter about AI
The sharpest AI news, curated daily. Delivered free to your inbox.